Pancreatic Neuroendocrine Tumor - 45 Studies Found
Recruiting |
: A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET) : Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours : 2014-09-23 :
|
Active, not recruiting |
: A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors : Well-differentiated Pancreatic Neuroendocrine Tumor : 2012-01-13 : Drug: sunitinib Sunitinib capsules will be given orally at continuous daily dosing with a starting dose |
Recruiting |
: A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus : Pancreatic Neuroendocrine Tumour Metastatic : 2014-06-17 : Drug: Everolimus 10 mg daily everolimus is a recently approved mTOR inhibitor in advanced progressing we |
Recruiting |
: Observational Study In Real Life Settings Of The Systemic Treatment Of Well Differentiated, Unresectable Or Metastatic, Progressive Pancreatic Neuroendocrine Tumors (pNET): A Study Of Morbidity And Mortality At 2 Years : Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive : 2014-09-02 :
|
Active, not recruiting |
: Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors :
|
Active, not recruiting |
: Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors : Non Functioning Pancreatic Endocrine Tumor : 2016-04-26 : Biological: Chromogranin A The plasma level of chromogranin A (CgA) was measured in enrolled patients wh |
Recruiting |
: Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery :
|
Completed |
: Comparative Study of Robotic, Laparoscopic and Open Surgery for Enucleation of Benign Pancreatic Neoplasms : Pancreatic Neuroendocrine Tumors : 2014-04-26 :
|
Recruiting |
: Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China : Pancreatic Neuroendocrine Tumors : 2016-06-16 : Drug: everolimus Everolimus is taken at a starting dose of 10 mg orally once daily.Patients will be prov |
Completed |
: An Analysis of Presentation and Outcome Following Treatment of Pancreatic Endocrine Neoplasms : Pancreatic Endocrine Neoplasms : 2015-03-23 |